News

Tekmira's Ebola jab unlikely to show benefit


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Tekmira's Ebola jab unlikely to show benefit

 

Date: 22/06/2015


Shares in Tekmira have taken a downturn after it emerged that its experimental Ebola vaccine was unlikely to hit efficacy goals in a mid-stage trial.

The Vancouver, Canada-based group said it has stopped enrolment in the Phase II, Sierra Leone-based trial after a predefined statistical endpoint indicated that there was not likely to be an overall therapeutic benefit from its jab.

For more click here

Source: Pharmatimes

© Catalyst Innovation Portal 2019